Laurie Pahus

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach. This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements. Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids. Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach. Severe asthma results in more airway inflammation, worse symptoms and lower lung function, despite increased therapy http://ow.ly/QznR3

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.

Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion. It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells. Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors. Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide. All have higher selectivity for M3 receptors than for M2 receptors, and dissociate more slowly from the M3 receptors than they do from the M2 receptors. Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-positive goblet cell number, decrease in MUC5AC overexpression). In the clinic, LAMAs showed a significant improvement of forced expiratory volume in 1 second (FEV1), quality of life, dyspnea and reduced the number of exacerbations in COPD and more recently in asthma. This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.

We Should Prohibit Warfarin in Idiopathic Pulmonary Fibrosis

1. Villacorta M, Misari J. Perú: mapa del déficit habitacional a Nivel Distrital, 2007. INEI, Lima, Perú, 2007. 2. Diette GB, Accinelli RA, Balmes JR, Buist AS, Checkley W, Garbe P, Hansel NN, Kapil V, Gordon S, Lagat DK, et al. Obstructive lung disease and exposure to burning biomass fuel in the indoor environment. Glob Heart 2012;7:265–270. 3. Guofeng S, Siye W, Wen W, Yanyan Z, Yujia M, Bin W, Rong W, Wei L, Huizhong S, Ye H, et al. Emission factors, size distributions, and emission inventories of carbonaceous particulate matter from residential wood combustion in rural China. Environ Sci Technol 2012; 46:4207–4214. 4. Karottki DG, Bekö G, Clausen G, Madsen AM, Andersen ZJ, Massling A, Ketzel M, Ellermann T, Lund R, Sigsgaard T, et al. Cardiovascular and lung function in relation to outdoor and indoor exposure to fine and ultrafine particulate matter in middle-aged subjects. Environ Int 2014; 73:372–381. 5. Lam NL, Chen Y, Weyant C, Venkataraman C, Sadavarte P, Johnson MA, Smith KR, Brem BT, Arineitwe J, Ellis JE, et al. Household light makes global heat: high black carbon emissions from kerosene wick lamps. Environ Sci Technol 2012;46: 13531–13538. 6. Dogan OT, Elagoz S, Ozsahin SL, Epozturk K, Tuncer E, Akkurt I. Pulmonary toxicity of chronic exposure to tobacco and biomass smoke in rats. Clinics (Sao Paulo) 2011;66: 1081–1087. 7. Smith-Sivertsen T, Dı́az E, Pope D, Lie RT, Dı́az A, McCracken J, Bakke P, Arana B, Smith KR, Bruce N. Effect of reducing indoor air pollution on women’s respiratory symptoms and lung function: the RESPIRE Randomized Trial, Guatemala. Am J Epidemiol 2009; 170:211–220. 8. Bruce N, Neufeld L, Boy E, West C. Indoor biofuel air pollution and respiratory health: the role of confounding factors among women in highland Guatemala. Int J Epidemiol 1998;27: 454–458. 9. Jacobsen KH, Ribeiro PS, Quist BK, Rydbeck BV. Prevalence of intestinal parasites in young Quichua children in the highlands of rural Ecuador. J Health Popul Nutr 2007;25: 399–405. 10. Gamboa MI, Kozubsky LE, Costas ME, Garraza M, Cardozo MI, Susevich ML, Magistrello PN, Navone GT. Asociación entre geohelmintos y condiciones socioambientales en diferentes poblaciones humanas de Argentina [Associations between geohelminths and socioenvironmental conditions among different human populations in Argentina]. Rev Panam Salud Publica 2009;26:1–8.

Mortality: a neglected outcome in OCS-treated severe asthma

Severe asthma, especially if associated with a T2 phenotype, often responds well to new emerging therapies, which have led to a reduction in the use of systemic oral corticosteroids (OCS) [1]. However, OCS-dependent patients still exist and are affected by the well-known (and potentially severe) side effects of such dependency. Longitudinal data that document the outcomes, including death, for these patients are lacking [2]. Here, we present our findings from a long-term severe asthma cohort, which indicate that mortality is a critical issue for these patients. Findings from a long-term severe asthma cohort indicate mortality is a critical issue for OCS-dependent patients http://ow.ly/rO8e30fZrPo